Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
7 drugs in development
By Therapeutic Area
top 2
R&D Momentum
63/100
Pipeline Velocity
27/100
Trial Completion Rate
69/100
Pipeline Concentration
43/100
Pipeline Freshness
0/100
Strategic Signals
Activity
Last 14 days
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)
Vorasidenib as Maintenance Treatment After First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma: a Placebo-controlled, Triple-blind, Randomized Phase III Study (VIGOR)
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Regulatory
Locoid — LOCOID
Application NDA018652 (NDA)
Locoid — LOCOID
Application NDA018514 (NDA)
Locoid — LOCOID
Application NDA018795 (NDA)
Locoid — LOCOID
Application NDA019106 (NDA)
Locoid — LOCOID
Application NDA019116 (NDA)
Locoid — LOCOID
Application NDA019819 (NDA)
Locoid — LOCOID LIPOCREAM
Application NDA020769 (NDA)
Locoid — LOCOID
Application NDA022076 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)